The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke

1.

Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30(43):10363–70. https://doi.org/10.1021/bi00107a001.CrossRefPubMed

2.

Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron. 1991;6(4):575–81. https://doi.org/10.1016/0896-6273(91)90060-d.CrossRefPubMed

3.

Weinstein JR, Gold SJ, Cunningham DD, Gall CM. Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. J Neurosci. 1995;15(4):2906–19.CrossRef

4.

Jamison CS, Degen SJ. Prenatal and postnatal expression of mRNA coding for rat prothrombin. Biochim Biophys Acta. 1991;1088(2):208–16. https://doi.org/10.1016/0167-4781(91)90056-r.CrossRefPubMed

5.

Maggio N, Itsekson Z, Dominissini D, Blatt I, Amariglio N, Rechavi G, et al. Thrombin regulation of synaptic plasticity: implications for physiology and pathology. Exp Neurol. 2013;247:595–604. https://doi.org/10.1016/j.expneurol.2013.02.011.CrossRefPubMed

6.

Ben Shimon M, Lenz M, Ikenberg B, Becker D, Shavit Stein E, Chapman J, et al. Thrombin regulation of synaptic transmission and plasticity: implications for health and disease. Front Cell Neurosci. 2015;9:151. https://doi.org/10.3389/fncel.2015.00151.CrossRefPubMedPubMedCentral

7.

Rajput PS, Lamb J, Kothari S, Pereira B, Soetkamp D, Wang Y, et al. Neuron-generated thrombin induces a protective astrocyte response via protease activated receptors. Glia. 2020;68(2):246–62. https://doi.org/10.1002/glia.23714.CrossRefPubMed

8.

Sokolova E, Reiser G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb Haemost. 2008;100(4):576–81.CrossRef

9.

Lee KR, Betz AL, Kim S, Keep RF, Hoff JT. The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage. Acta Neurochir (Wien). 1996;138(4):396–400; discussion −1. https://doi.org/10.1007/bf01420301.CrossRef

10.

Keep RF, Xiang J, Ennis SR, Andjelkovic A, Hua Y, Xi G, et al. Blood-brain barrier function in intracerebral hemorrhage. Acta Neurochir Suppl. 2008;105:73–7. https://doi.org/10.1007/978-3-211-09469-3_15.CrossRefPubMed

11.

Chen B, Cheng Q, Yang K, Lyden PD. Thrombin mediates severe neurovascular injury during ischemia. Stroke. 2010;41(10):2348–52. https://doi.org/10.1161/STROKEAHA.110.584920.CrossRefPubMed

12.

Krenzlin H, Lorenz V, Danckwardt S, Kempski O, Alessandri B. The importance of thrombin in cerebral injury and disease. Int J Mol Sci. 2016;17(1):84. https://doi.org/10.3390/ijms17010084.CrossRefPubMedCentral

13.

Striggow F, Riek M, Breder J, Henrich-Noack P, Reymann KG, Reiser G. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proc Natl Acad Sci U S A. 2000;97(5):2264–9. https://doi.org/10.1073/pnas.040552897.CrossRefPubMedPubMedCentral

14.

Xi G, Keep RF, Hua Y, Xiang J, Hoff JT. Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. Stroke. 1999;30(6):1247–55. https://doi.org/10.1161/01.str.30.6.1247.CrossRefPubMed

15.

Bao X, Hua Y, Keep RF, Xi G. Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1. Conditioning medicine. 2018;1(2):57–63.PubMedPubMedCentral

16.

Lee KR, Kawai N, Kim S, Sagher O, Hoff JT. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg. 1997;86(2):272–8. https://doi.org/10.3171/jns.1997.86.2.0272.CrossRefPubMed

17.

Xi G, Wagner KR, Keep RF, Hua Y, de Courten-Myers GM, Broderick JP, et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke. 1998;29(12):2580–6. https://doi.org/10.1161/01.str.29.12.2580.CrossRefPubMed

18.

Hua Y, Wu J, Keep RF, Hoff JT, Xi G. Thrombin exacerbates brain edema in focal cerebral ischemia. Acta Neurochir Suppl. 2003;86:163–6. https://doi.org/10.1007/978-3-7091-0651-8_34.CrossRefPubMed

19.

Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci. 1995;15(7 Pt 2):5389–401.CrossRef

20.

Thevenet J, Angelillo-Scherrer A, Price M, Hirt L. Coagulation factor Xa activates thrombin in ischemic neural tissue. J Neurochem. 2009;111(3):828–36. https://doi.org/10.1111/j.1471-4159.2009.06369.x.CrossRefPubMed

21.

Fenton JW 2nd. Thrombin. Ann N Y Acad Sci. 1986;485:5–15. https://doi.org/10.1111/j.1749-6632.1986.tb34563.x.CrossRefPubMed

22.

Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114(12):2367–74. https://doi.org/10.1182/blood-2009-05-199208.CrossRefPubMed

23.

Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem. 2003;84(1):3–9. https://doi.org/10.1046/j.1471-4159.2003.01268.x.CrossRefPubMed

24.

Burzynski LC, Humphry M, Pyrillou K, Wiggins KA, Chan JNE, Figg N, et al. The coagulation and immune systems are directly linked through the activation of interleukin-1alpha by thrombin. Immunity. 2019;50(4):1033–42.e6. https://doi.org/10.1016/j.immuni.2019.03.003.CrossRefPubMedPubMedCentral

25.

Petzold T, Massberg S. Thrombin: a gas pedal driving innate immunity. Immunity. 2019;50(4):1024–6. https://doi.org/10.1016/j.immuni.2019.03.006.CrossRefPubMed

26.

van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res. 2000;87(4):335–40. https://doi.org/10.1161/01.res.87.4.335.CrossRefPubMed

27.

Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019;393(10175):1021–32. https://doi.org/10.1016/S0140-6736(19)30195-3.CrossRefPubMedPubMedCentral

28.

Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. 2012;3:1227. https://doi.org/10.1038/ncomms2230.CrossRefPubMedPubMedCentral

29.

Ryu JK, Petersen MA, Murray SG, Baeten KM, Meyer-Franke A, Chan JP, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015;6:8164. https://doi.org/10.1038/ncomms9164.CrossRefPubMedPubMedCentral

30.

Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19(5):283–301. https://doi.org/10.1038/nrn.2018.13.CrossRefPubMedPubMedCentral

31.

Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258–64. https://doi.org/10.1038/35025229.CrossRefPubMed

32.

Carney DH, Cunningham DD. Role of specific cell surface receptors in thrombin-stimulated cell division. Cell. 1978;15(4):1341–9. https://doi.org/10.1016/0092-8674(78)90059-4.CrossRefPubMed

33.

Wang H, Ubl JJ, Reiser G. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia. 2002;37(1):53–63. https://doi.org/10.1002/glia.10012.CrossRefPubMed

34.

Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004;84(2):579–621. https://doi.org/10.1152/physrev.00028.2003.CrossRefPubMed

35.

Posma JJ, Posthuma JJ, Spronk HM. Coagulation and non-coagulation effects of thrombin. J Thromb Haemost. 2016;14(10):1908–16. https://doi.org/10.1111/jth.13441.CrossRefPubMed

36.

van den Biggelaar M, Hernandez-Fernaud JR, van den Eshof BL, Neilson LJ, Meijer AB, Mertens K, et al. Quantitative phosphoproteomics unveils temporal dynamics of thrombin signaling in human endothelial cells. Blood. 2014;123(12):e22–36. https://doi.org/10.1182/blood-2013-12-546036.CrossRefPubMedPubMedCentral

37.

Striggow F, Riek-Burchardt M, Kiesel A, Schmidt W, Henrich-Noack P, Breder J, et al. Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur J Neurosci. 2001;14(4):595–608. https://doi.org/10.1046/j.0953-816x.2001.01676.x.CrossRefPubMed

38.

Suo Z, Wu M, Ameenuddin S, Anderson HE, Zoloty JE, Citron BA, et al. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem. 2002;80(4):655–66. https://doi.org/10.1046/j.0022-3042.2001.00745.x.CrossRefPubMed

39.

Wang H, Ubl JJ, Stricker R, Reiser G. Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. Am J Physiol Cell Physiol. 2002;283(5):C1351–64. https://doi.org/10.1152/ajpcell.00001.2002.CrossRefPubMed

40.

Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359–69. https://doi.org/10.1038/s41593-018-0242-x.CrossRefPubMedPubMedCentral

41.

Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev. 2007;56(2):331–45. https://doi.org/10.1016/j.brainresrev.2007.08.002.CrossRefPubMed

42.

Wang Y, Luo W, Stricker R, Reiser G. Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1. J Neurochem. 2006;98(4):1046–60. https://doi.org/10.1111/j.1471-4159.2006.03950.x.CrossRefPubMed

43.

Donovan FM, Pike CJ, Cotman CW, Cunningham DD. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J Neurosci. 1997;17(14):5316–26.CrossRef

44.

Nicole O, Goldshmidt A, Hamill CE, Sorensen SD, Sastre A, Lyuboslavsky P, et al. Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J Neurosci. 2005;25(17):4319–29. https://doi.org/10.1523/JNEUROSCI.5200-04.2005.CrossRefPubMedPubMedCentral

45.

Brailoiu E, Shipsky MM, Yan G, Abood ME, Brailoiu GC. Mechanisms of modulation of brain microvascular endothelial cells function by thrombin. Brain Res. 1657;2017:167–75. https://doi.org/10.1016/j.brainres.2016.12.011.CrossRef

46.

Puech C, Delavenne X, He Z, Forest V, Mismetti P, Perek N. Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway. Brain Res. 1719;2019:57–63. https://doi.org/10.1016/j.brainres.2019.05.024.CrossRef

47.

Amar AP, Sagare AP, Zhao Z, Wang Y, Nelson AR, Griffin JH, et al. Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. Neuropharmacology. 2018;134(Pt B):293–301. https://doi.org/10.1016/j.neuropharm.2017.09.021.CrossRefPubMed

48.

Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, et al. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke. 2013;44(12):3529–36. https://doi.org/10.1161/STROKEAHA.113.003350.CrossRefPubMedPubMedCentral

49.

Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, et al. Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. Ann Neurol. 2019;85(1):125–36. https://doi.org/10.1002/ana.25383.CrossRefPubMedPubMedCentral

50.

Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 degrees P-TIMI 50 trial. J Am Coll Cardiol. 2014;64(22):2318–26. https://doi.org/10.1016/j.jacc.2014.07.997.CrossRefPubMed

51.

Jiang Y, Wu J, Hua Y, Keep RF, Xiang J, Hoff JT, et al. Thrombin-receptor activation and thrombin-induced brain tolerance. J Cereb Blood Flow Metab. 2002;22(4):404–10. https://doi.org/10.1097/00004647-200204000-00004.CrossRefPubMed

52.

Pike CJ, Vaughan PJ, Cunningham DD, Cotman CW. Thrombin attenuates neuronal cell death and modulates astrocyte reactivity induced by beta-amyloid in vitro. J Neurochem. 1996;66(4):1374–82. https://doi.org/10.1046/j.1471-4159.1996.66041374.x.CrossRefPubMed

53.

Masada T, Xi G, Hua Y, Keep RF. The effects of thrombin preconditioning on focal cerebral ischemia in rats. Brain Res. 2000;867(1–2):173–9 S0006-8993(00)02302-7 [pii].CrossRef

54.

Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res. 2001;89(1):47–54. https://doi.org/10.1161/hh1301.092678.CrossRefPubMed

55.

Jiang Y, Wu J, Keep RF, Hua Y, Hoff JT, Xi G. Hypoxia-inducible factor-1alpha accumulation in the brain after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab. 2002;22(6):689–96. https://doi.org/10.1097/00004647-200206000-00007.CrossRefPubMed

56.

Hua Y, Keep RF, Hoff JT, Xi G. Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. J Cereb Blood Flow Metab. 2003;23(12):1448–54. https://doi.org/10.1097/01.WCB.0000090621.86921.D5.CrossRefPubMed

57.

Zhou HJ, Tang T, Cui HJ, Yang AL, Luo JK, Lin Y, et al. Thrombin-triggered angiogenesis in rat brains following experimental intracerebral hemorrhage. J Neurosurg. 2012;117(5):920–8. https://doi.org/10.3171/2012.8.JNS112152.CrossRefPubMed

58.

Hua Y, Xi G, Keep RF, Wu J, Jiang Y, Hoff JT. Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab. 2002;22(1):55–61. https://doi.org/10.1097/00004647-200201000-00007.CrossRefPubMed

59.

Hoffmann MC, Nitsch C, Scotti AL, Reinhard E, Monard D. The prolonged presence of glia-derived nexin, an endogenous protease inhibitor, in the hippocampus after ischemia-induced delayed neuronal death. Neuroscience. 1992;49(2):397–408. https://doi.org/10.1016/0306-4522(92)90105-b.CrossRefPubMed

60.

Wang Y, Luo W, Reiser G. Activation of protease-activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth-regulated oncogene/cytokine-induced neutrophil chemoattractant family. Eur J Neurosci. 2007;26(11):3159–68. https://doi.org/10.1111/j.1460-9568.2007.05938.x.CrossRefPubMed

61.

Malik A, Kanneganti TD. Function and regulation of IL-1alpha in inflammatory diseases and cancer. Immunol Rev. 2018;281(1):124–37. https://doi.org/10.1111/imr.12615.CrossRefPubMedPubMedCentral

62.

Conway EM. Thrombin: coagulation’s master regulator of innate immunity. J Thromb Haemost. 2019;17(11):1785–9. https://doi.org/10.1111/jth.14586.CrossRefPubMed

63.

Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A. 1986;83(10):3460–4. https://doi.org/10.1073/pnas.83.10.3460.CrossRefPubMedPubMedCentral

64.

Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci. 2001;21(15):5528–34.CrossRef

65.

Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood. 2010;115(17):3632–9. https://doi.org/10.1182/blood-2009-11-252643.CrossRefPubMed

66.

Weinstock DM, Chang P, Aronson DL, Kessler CM. Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol. 1998;57(3):193–9. https://doi.org/10.1002/(sici)1096-8652(199803)57:3<193::aid-ajh2>3.0.co;2-q.CrossRefPubMed

67.

Gong Y, Xi G, Hu H, Gu Y, Huang F, Keep RF, et al. Increase in brain thrombin activity after experimental intracerebral hemorrhage. Acta Neurochir Suppl. 2008;105:47–50. https://doi.org/10.1007/978-3-211-09469-3_10.CrossRefPubMed

68.

Festoff BW, Smirnova IV, Ma J, Citron BA. Thrombin, its receptor and protease nexin I, its potent serpin, in the nervous system. Semin Thromb Hemost. 1996;22(3):267–71. https://doi.org/10.1055/s-2007-999018.CrossRefPubMed

69.

Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem. 1996;271(38):23121–5. https://doi.org/10.1074/jbc.271.38.23121.CrossRefPubMed

70.

Wilkinson DA, Pandey AS, Thompson BG, Keep RF, Hua Y, Xi G. Injury mechanisms in acute intracerebral hemorrhage. Neuropharmacology. 2018;134(Pt B):240–8. https://doi.org/10.1016/j.neuropharm.2017.09.033.CrossRefPubMed

71.

Gong C, Boulis N, Qian J, Turner DE, Hoff JT, Keep RF. Intracerebral hemorrhage-induced neuronal death. Neurosurgery. 2001;48(4):875–82; discussion 82-3. https://doi.org/10.1097/00006123-200104000-00037.CrossRefPubMed

72.

Kitaoka T, Hua Y, Xi G, Hoff JT, Keep RF. Delayed argatroban treatment reduces edema in a rat model of intracerebral hemorrhage. Stroke. 2002;33(12):3012–8. https://doi.org/10.1161/01.str.0000037673.17260.1b.CrossRefPubMed

73.

Nagatsuna T, Nomura S, Suehiro E, Fujisawa H, Koizumi H, Suzuki M. Systemic administration of argatroban reduces secondary brain damage in a rat model of intracerebral hemorrhage: histopathological assessment. Cerebrovasc Dis. 2005;19(3):192–200. https://doi.org/10.1159/000083466.CrossRefPubMed

74.

Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G. Behavioral tests after intracerebral hemorrhage in the rat. Stroke. 2002;33(10):2478–84. https://doi.org/10.1161/01.str.0000032302.91894.0f.CrossRefPubMed

75.

Hua Y, Keep RF, Hoff JT, Xi G. Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke. 2007;38(2 Suppl):759–62. https://doi.org/10.1161/01.STR.0000247868.97078.10.CrossRefPubMed

76.

Nakamura T, Xi G, Park JW, Hua Y, Hoff JT, Keep RF. Holo-transferrin and thrombin can interact to cause brain damage. Stroke. 2005;36(2):348–52. https://doi.org/10.1161/01.STR.0000153044.60858.1b.CrossRefPubMed

77.

Mao S, Xi G, Keep RF, Hua Y. Role of lipocalin-2 in thrombin-induced brain injury. Stroke. 2016;47(4):1078–84. https://doi.org/10.1161/STROKEAHA.115.012153.CrossRefPubMedPubMedCentral

78.

Manning L, Hirakawa Y, Arima H, Wang X, Chalmers J, Wang J, et al. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol. 2014;13(4):364–73. https://doi.org/10.1016/S1474-4422(14)70018-3.CrossRefPubMed

79.

Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53–63. https://doi.org/10.1016/S1474-4422(05)70283-0.CrossRefPubMed

80.

Hua Y, Wu J, Keep RF, Nakamura T, Hoff JT, Xi G. Tumor necrosis factor-alpha increases in the brain after intracerebral hemorrhage and thrombin stimulation. Neurosurgery. 2006;58(3):542–50; discussion -50. https://doi.org/10.1227/01.Neu.0000197333.55473.Ad.CrossRefPubMed

81.

Wu J, Yang S, Xi G, Song S, Fu G, Keep RF, et al. Microglial activation and brain injury after intracerebral hemorrhage. Acta Neurochir Suppl. 2008;105:59–65. https://doi.org/10.1007/978-3-211-09469-3_13.CrossRefPubMed

82.

Gong Y, Xi GH, Keep RF, Hoff JT, Hua Y. Complement inhibition attenuates brain edema and neurological deficits induced by thrombin. Acta Neurochir Suppl. 2005;95:389–92. https://doi.org/10.1007/3-211-32318-x_79.CrossRefPubMed

83.

Giulian D, Baker TJ. Peptides released by ameboid microglia regulate astroglial proliferation. J Cell Biol. 1985;101(6):2411–5. https://doi.org/10.1083/jcb.101.6.2411.CrossRefPubMed

84.

Patel HC, Boutin H, Allan SM. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci. 2003;992:39–47. https://doi.org/10.1111/j.1749-6632.2003.tb03136.x.CrossRefPubMed

85.

Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000;23(12):618–25. https://doi.org/10.1016/s0166-2236(00)01661-1.CrossRefPubMed

86.

Masada T, Hua Y, Xi G, Yang GY, Hoff JT, Keep RF. Attenuation of intracerebral hemorrhage and thrombin-induced brain edema by overexpression of interleukin-1 receptor antagonist. J Neurosurg. 2001;95(4):680–6. https://doi.org/10.3171/jns.2001.95.4.0680.CrossRefPubMed

87.

Cheng Y, Xi G, Jin H, Keep RF, Feng J, Hua Y. Thrombin-induced cerebral hemorrhage: role of protease-activated receptor-1. Transl Stroke Res. 2014;5(4):472–5. https://doi.org/10.1007/s12975-013-0288-8.CrossRefPubMed

88.

Wan S, Cheng Y, Jin H, Guo D, Hua Y, Keep RF, et al. Microglia activation and polarization after intracerebral hemorrhage in mice: the role of protease-activated receptor-1. Transl Stroke Res. 2016;7(6):478–87. https://doi.org/10.1007/s12975-016-0472-8.CrossRefPubMedPubMedCentral

89.

Gingrich MB, Junge CE, Lyuboslavsky P, Traynelis SF. Potentiation of NMDA receptor function by the serine protease thrombin. J Neurosci. 2000;20(12):4582–95.CrossRef

90.

Lauer A, Cianchetti FA, Van Cott EM, Schlunk F, Schulz E, Pfeilschifter W, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation. 2011;124(15):1654–62. https://doi.org/10.1161/CIRCULATIONAHA.111.035972.CrossRefPubMedPubMedCentral

91.

Schlunk F, Bohm M, Boulouis G, Qin T, Arbel M, Tamim I, et al. Secondary bleeding during acute experimental intracerebral hemorrhage. Stroke. 2019;50(5):1210–5. https://doi.org/10.1161/STROKEAHA.118.021732.CrossRefPubMedPubMedCentral

92.

Bao X, Ye F, Wan S, Hua Y, Keep R, Garton HJL, et al. Role of protease activated receptor-1 in thrombin preconditioning against thrombin-induced brain injury in mice. Conditioning medicine. 2019;2(5):185–91.

93.

Yang S, Hua Y, Nakamura T, Keep RF, Xi G. Up-regulation of brain ceruloplasmin in thrombin preconditioning. Acta Neurochir Suppl. 2006;96:203–6.CrossRef

94.

Liu H, Hua Y, Keep RF, Xi G. Brain ceruloplasmin expression after experimental intracerebral hemorrhage and protection against iron-induced brain injury. Transl Stroke Res. 2019;10(1):112–9. https://doi.org/10.1007/s12975-018-0669-0.CrossRefPubMed

95.

Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 2010;92(4):463–77. https://doi.org/10.1016/j.pneurobio.2010.08.001.CrossRefPubMedPubMedCentral

96.

Zhou Y, Wang Y, Wang J, Anne Stetler R, Yang QW. Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation. Prog Neurobiol. 2014;115:25–44. https://doi.org/10.1016/j.pneurobio.2013.11.003.CrossRefPubMed

97.

Strahle J, Garton HJ, Maher CO, Muraszko KM, Keep RF, Xi G. Mechanisms of hydrocephalus after neonatal and adult intraventricular hemorrhage. Transl Stroke Res. 2012;3(Suppl 1):25–38. https://doi.org/10.1007/s12975-012-0182-9.CrossRefPubMedPubMedCentral

98.

Garton T, Hua Y, Xiang J, Xi G, Keep RF. Challenges for intraventricular hemorrhage research and emerging therapeutic targets. Expert Opin Ther Targets. 2017;21(12):1111–22. https://doi.org/10.1080/14728222.2017.1397628.CrossRefPubMedPubMedCentral

99.

Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke. 2009;40(4):1533–8. https://doi.org/10.1161/STROKEAHA.108.535419.CrossRefPubMedPubMedCentral

100.

Rosen DS, Macdonald RL, Huo D, Goldenberg FD, Novakovic RL, Frank JI, et al. Intraventricular hemorrhage from ruptured aneurysm: clinical characteristics, complications, and outcomes in a large, prospective, multicenter study population. J Neurosurg. 2007;107(2):261–5. https://doi.org/10.3171/JNS-07/08/0261.CrossRefPubMed

101.

Mayfrank L, Kissler J, Raoofi R, Delsing P, Weis J, Kuker W, et al. Ventricular dilatation in experimental intraventricular hemorrhage in pigs. Characterization of cerebrospinal fluid dynamics and the effects of fibrinolytic treatment. Stroke. 1997;28(1):141–8. https://doi.org/10.1161/01.str.28.1.141.CrossRefPubMed

102.

Hanley DF, Lane K, McBee N, Ziai W, Tuhrim S, Lees KR, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017;389(10069):603–11. https://doi.org/10.1016/S0140-6736(16)32410-2.CrossRefPubMedPubMedCentral

103.

Mazzola CA, Choudhri AF, Auguste KI, Limbrick DD Jr, Rogido M, Mitchell L, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: management of posthemorrhagic hydrocephalus in premature infants. J Neurosurg Pediatr. 2014;14(Suppl 1):8–23. https://doi.org/10.3171/2014.7.PEDS14322.CrossRefPubMed

104.

Neary E, McCallion N, Kevane B, Cotter M, Egan K, Regan I, et al. Coagulation indices in very preterm infants from cord blood and postnatal samples. J Thromb Haemost. 2015;13(11):2021–30. https://doi.org/10.1111/jth.13130.CrossRefPubMed

105.

Bruschettini M, Romantsik O, Zappettini S, Banzi R, Ramenghi LA, Calevo MG. Heparin for the prevention of intraventricular haemorrhage in preterm infants. The Cochrane database of systematic reviews. 2016;5:Cd011718. https://doi.org/10.1002/14651858.CD011718.pub2.CrossRef

106.

Bruschettini M, Romantsik O, Zappettini S, Banzi R, Ramenghi LA, Calevo MG. Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants. The Cochrane database of systematic reviews. 2016;3:Cd011636. https://doi.org/10.1002/14651858.CD011636.pub2.CrossRefPubMed

107.

Gao F, Liu F, Chen Z, Hua Y, Keep RF, Xi G. Hydrocephalus after intraventricular hemorrhage: the role of thrombin. J Cereb Blood Flow Metab. 2014;34(3):489–94. https://doi.org/10.1038/jcbfm.2013.225.CrossRefPubMed

108.

Liu DZ, Ander BP, Xu H, Shen Y, Kaur P, Deng W, et al. Blood-brain barrier breakdown and repair by Src after thrombin-induced injury. Ann Neurol. 2010;67(4):526–33. https://doi.org/10.1002/ana.21924.CrossRefPubMedPubMedCentral

109.

Liu DZ, Waldau B, Ander BP, Zhan X, Stamova B, Jickling GC, et al. Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin. J Cereb Blood Flow Metab. 2017;37(7):2359–67. https://doi.org/10.1177/0271678X16666291.CrossRefPubMed

110.

Xue M, Balasubramaniam J, Parsons KA, McIntyre IW, Peeling J, Del Bigio MR. Does thrombin play a role in the pathogenesis of brain damage after periventricular hemorrhage? Brain Pathol. 2005;15(3):241–9. https://doi.org/10.1111/j.1750-3639.2005.tb00527.x.CrossRefPubMed

111.

Lekic T, Manaenko A, Rolland W, Krafft PR, Peters R, Hartman RE, et al. Rodent neonatal germinal matrix hemorrhage mimics the human brain injury, neurological consequences, and post-hemorrhagic hydrocephalus. Exp Neurol. 2012;236(1):69–78. https://doi.org/10.1016/j.expneurol.2012.04.003.CrossRefPubMedPubMedCentral

112.

Lekic T, Krafft PR, Klebe D, Flores J, Rolland WB, Tang J, et al. PAR-1, -4, and the mTOR pathway following germinal matrix hemorrhage. Acta Neurochir Suppl. 2016;121:213–6. https://doi.org/10.1007/978-3-319-18497-5_38.CrossRefPubMed

113.

Klebe D, Flores JJ, McBride DW, Krafft PR, Rolland WB, Lekic T, et al. Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups. J Cereb Blood Flow Metab. 2017;37(9):3135–49. https://doi.org/10.1177/0271678X16684355.CrossRefPubMed

114.

Karimy JK, Zhang J, Kurland DB, Theriault BC, Duran D, Stokum JA, et al. Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus. Nat Med. 2017;23(8):997–1003. https://doi.org/10.1038/nm.4361.CrossRefPubMed

115.

Gao F, Zheng M, Hua Y, Keep RF, Xi G. Acetazolamide attenuates thrombin-induced hydrocephalus. Acta Neurochir Suppl. 2016;121:373–7. https://doi.org/10.1007/978-3-319-18497-5_64.CrossRefPubMed

116.

Wan Y, Hua Y, Garton HJL, Novakovic N, Keep RF, Xi G. Activation of epiplexus macrophages in hydrocephalus caused by subarachnoid hemorrhage and thrombin. CNS neuroscience & therapeutics. 2019;25(10):1134–41. https://doi.org/10.1111/cns.13203.CrossRef

117.

Hao XD, Le CS, Zhang HM, Shang DS, Tong LS, Gao F. Thrombin disrupts vascular endothelial-cadherin and leads to hydrocephalus via protease-activated receptors-1 pathway. CNS neuroscience & therapeutics. 2019;25(10):1142–50. https://doi.org/10.1111/cns.13129.CrossRef

118.

Wan Y, Gao F, Ye F, Yang W, Hua Y, Keep RF, et al. Effects of aging on hydrocephalus after intraventricular hemorrhage. Fluids and barriers of the CNS. 2020;17(1):8. https://doi.org/10.1186/s12987-020-0169-y.CrossRefPubMedPubMedCentral

119.

Suzuki M, Kudo A, Otawara Y, Hirashima Y, Takaku A, Ogawa A. Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery. 1999;44(3):487–93; discussion 93-4. https://doi.org/10.1097/00006123-199903000-00029.CrossRefPubMed

120.

Ikeda K, Asakura H, Futami K, Yamashita J. Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage. Neurosurgery. 1997;41(2):344–9; discussion 9-50. https://doi.org/10.1097/00006123-199708000-00002.CrossRefPubMed

121.

Peterson EW, Cardoso ER. The blood-brain barrier following experimental subarachnoid hemorrhage. Part 1: response to insult caused by arterial hypertension. J Neurosurg. 1983;58(3):338–44. https://doi.org/10.3171/jns.1983.58.3.0338.CrossRefPubMed

122.

Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006;26(11):1341–53. https://doi.org/10.1038/sj.jcbfm.9600283.CrossRefPubMed

123.

Helbok R, Ko SB, Schmidt JM, Kurtz P, Fernandez L, Choi HA, et al. Global cerebral edema and brain metabolism after subarachnoid hemorrhage. Stroke. 2011;42(6):1534–9. https://doi.org/10.1161/STROKEAHA.110.604488.CrossRefPubMed

124.

Sugawara T, Jadhav V, Ayer R, Chen W, Suzuki H, Zhang JH. Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. Stroke. 2009;40(4):1530–2. https://doi.org/10.1161/strokeaha.108.531699.CrossRefPubMedPubMedCentral

125.

Yan J, Manaenko A, Chen S, Klebe D, Ma Q, Caner B, et al. Role of SCH79797 in maintaining vascular integrity in rat model of subarachnoid hemorrhage. Stroke. 2013;44(5):1410–7. https://doi.org/10.1161/STROKEAHA.113.678474.CrossRefPubMedPubMedCentral

126.

Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res. 2009;87(1):1–11. https://doi.org/10.1002/jnr.21823.CrossRefPubMed

127.

Danura H, Schatlo B, Marbacher S, Kerkeni H, Diepers M, Remonda L, et al. Acute angiographic vasospasm and the incidence of delayed cerebral vasospasm: preliminary results. Acta Neurochir Suppl. 2015;120:187–90. https://doi.org/10.1007/978-3-319-04981-6_32.CrossRefPubMed

128.

Hirano K, Hirano M. Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. J Pharmacol Sci. 2010;114(2):127–33. https://doi.org/10.1254/jphs.10r03cp.CrossRefPubMed

129.

Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990;248(4958):1009–12. https://doi.org/10.1126/science.2343305.CrossRefPubMed

130.

Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–312. https://doi.org/10.1101/gad.1653708.CrossRefPubMedPubMedCentral

131.

Suzuki S, Suzuki M, Iwabuchi T, Kamata Y. Role of multiple cerebral microthrombosis in symptomatic cerebral vasospasm: with a case report. Neurosurgery. 1983;13(2):199–203. https://doi.org/10.1227/00006123-198308000-00018.CrossRefPubMed

132.

Suzuki S, Kimura M, Souma M, Ohkima H, Shimizu T, Iwabuchi T. Cerebral microthrombosis in symptomatic cerebral vasospasm--a quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo). 1990;30(5):309–16. https://doi.org/10.2176/nmc.30.309.CrossRef

133.

Friedrich B, Muller F, Feiler S, Scholler K, Plesnila N. Experimental subarachnoid hemorrhage causes early and long-lasting microarterial constriction and microthrombosis: an in-vivo microscopy study. J Cereb Blood Flow Metab. 2012;32(3):447–55. https://doi.org/10.1038/jcbfm.2011.154.CrossRefPubMed

134.

Guo D, Wilkinson DA, Thompson BG, Pandey AS, Keep RF, Xi G, et al. MRI characterization in the acute phase of experimental subarachnoid hemorrhage. Transl Stroke Res. 2017;8(3):234–43. https://doi.org/10.1007/s12975-016-0511-5.CrossRefPubMed

135.

Clarke JV, Suggs JM, Diwan D, Lee JV, Lipsey K, Vellimana AK, et al. Microvascular platelet aggregation and thrombosis after subarachnoid hemorrhage: a review and synthesis. J Cereb Blood Flow Metab. 2020:271678X20921974. https://doi.org/10.1177/0271678X20921974.

136.

Sehba FA, Mostafa G, Friedrich V Jr, Bederson JB. Acute microvascular platelet aggregation after subarachnoid hemorrhage. J Neurosurg. 2005;102(6):1094–100. https://doi.org/10.3171/jns.2005.102.6.1094.CrossRefPubMed

137.

Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, et al. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology. 2002;59(11):1750–8. https://doi.org/10.1212/01.wnl.0000035748.91128.c2.CrossRefPubMed

138.

Brathwaite S, Macdonald RL. Current management of delayed cerebral ischemia: update from results of recent clinical trials. Transl Stroke Res. 2014;5(2):207–26. https://doi.org/10.1007/s12975-013-0316-8.CrossRefPubMed

139.

Dienel A, Ammassam Veettil R, Hong SH, Matsumura K, Kumar TP, Yan Y, et al. Microthrombi correlates with infarction and delayed neurological deficits after subarachnoid hemorrhage in mice. Stroke. 2020;51(7):2249–54. https://doi.org/10.1161/STROKEAHA.120.029753.CrossRefPubMed

140.

Dasenbrock HH, Angriman F, Smith TR, Gormley WB, Frerichs KU, Aziz-Sultan MA, et al. Readmission after aneurysmal subarachnoid hemorrhage: a Nationwide Readmission Database analysis. Stroke. 2017;48(9):2383–90. https://doi.org/10.1161/STROKEAHA.117.016702.CrossRefPubMed

141.

Adil SM, Liu B, Charalambous LT, Kiyani M, Gramer R, Swisher CB, et al. Healthcare economics of hydrocephalus after aneurysmal subarachnoid hemorrhage in the United States. Transl Stroke Res. 2019;10(6):650–63. https://doi.org/10.1007/s12975-019-00697-9.CrossRefPubMed

142.

Okubo S, Strahle J, Keep RF, Hua Y, Xi G. Subarachnoid hemorrhage-induced hydrocephalus in rats. Stroke. 2013;44(2):547–50. https://doi.org/10.1161/STROKEAHA.112.662312.CrossRefPubMed

143.

Golanov EV, Bovshik EI, Wong KK, Pautler RG, Foster CH, Federley RG, et al. Subarachnoid hemorrhage - induced block of cerebrospinal fluid flow: role of brain coagulation factor III (tissue factor). J Cereb Blood Flow Metab. 2018;38(5):793–808. https://doi.org/10.1177/0271678X17701157.CrossRefPubMed

144.

Thomas AJ, Ogilvy CS, Griessenauer CJ, Hanafy KA. Macrophage CD163 expression in cerebrospinal fluid: association with subarachnoid hemorrhage outcome. J Neurosurg. 2018;131(1):47–53. https://doi.org/10.3171/2018.2.JNS172828.CrossRefPubMed

145.

Mohme M, Sauvigny T, Mader MM, Schweingruber N, Maire CL, Runger A, et al. Immune characterization in aneurysmal subarachnoid hemorrhage reveals distinct monocytic activation and chemokine patterns. Transl Stroke Res. 2019. https://doi.org/10.1007/s12975-019-00764-1.

146.

Tsurutani H, Ohkuma H, Suzuki S. Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke. 2003;34(6):1497–500. https://doi.org/10.1161/01.Str.0000070424.38138.30.CrossRefPubMed

147.

Kameda K, Kikkawa Y, Hirano M, Matsuo S, Sasaki T, Hirano K. Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid haemorrhage. Br J Pharmacol. 2012;165(1):106–19. https://doi.org/10.1111/j.1476-5381.2011.01485.x.CrossRefPubMedPubMedCentral

148.

Zhang Z, Nagata I, Kikuchi H, Xue JH, Sakai N, Sakai H, et al. Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. Stroke. 2001;32(7):1665–72. https://doi.org/10.1161/01.str.32.7.1665.CrossRefPubMed

149.

Simard JM, Tosun C, Ivanova S, Kurland DB, Hong C, Radecki L, et al. Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage. Transl Stroke Res. 2012;3(Suppl 1):155–65. https://doi.org/10.1007/s12975-012-0166-9.CrossRefPubMedPubMedCentral

150.

Simard JM, Aldrich EF, Schreibman D, James RF, Polifka A, Beaty N. Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. J Neurosurg. 2013;119(6):1611–9. https://doi.org/10.3171/2013.8.JNS1337.CrossRefPubMedPubMedCentral

151.

James RF, Khattar NK, Aljuboori ZS, Page PS, Shao EY, Carter LM, et al. Continuous infusion of low-dose unfractionated heparin after aneurysmal subarachnoid hemorrhage: a preliminary study of cognitive outcomes. J Neurosurg. 2018:1–8. https://doi.org/10.3171/2017.11.JNS17894.

152.

Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg. 2003;99(6):953–9. https://doi.org/10.3171/jns.2003.99.6.0953.CrossRefPubMed

153.

Wurm G, Tomancok B, Nussbaumer K, Adelwohrer C, Holl K. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg. 2004;106(2):97–103. https://doi.org/10.1016/j.clineuro.2004.01.006.CrossRefPubMed

154.

Lindbohm JV, Kaprio J, Jousilahti P, Salomaa V, Korja M. Sex, smoking, and risk for subarachnoid hemorrhage. Stroke. 2016;47(8):1975–81. https://doi.org/10.1161/STROKEAHA.116.012957.CrossRefPubMed

155.

Sundstrom J, Soderholm M, Soderberg S, Alfredsson L, Andersson M, Bellocco R, et al. Risk factors for subarachnoid haemorrhage: a nationwide cohort of 950 000 adults. Int J Epidemiol. 2019;48(6):2018–25. https://doi.org/10.1093/ije/dyz163.CrossRefPubMed

156.

Turan N, Heider RA, Zaharieva D, Ahmad FU, Barrow DL, Pradilla G. Sex differences in the formation of intracranial aneurysms and incidence and outcome of subarachnoid hemorrhage: review of experimental and human studies. Transl Stroke Res. 2016;7(1):12–9. https://doi.org/10.1007/s12975-015-0434-6.CrossRefPubMed

157.

Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, et al. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol. 2013;12(6):539–45. https://doi.org/10.1016/S1474-4422(13)70079-6.CrossRefPubMedPubMedCentral

158.

Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. The Cochrane database of systematic reviews. 2015;3:CD000024. https://doi.org/10.1002/14651858.CD000024.pub4.CrossRef

159.

Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S–e36S. https://doi.org/10.1378/chest.11-2302.CrossRefPubMedPubMedCentral

160.

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–418. https://doi.org/10.1161/STR.0000000000000211.CrossRefPubMed

161.

Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012;43(3):770–5. https://doi.org/10.1161/STROKEAHA.111.625574.CrossRefPubMedPubMedCentral

162.

Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, et al. Randomized, multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke). Stroke. 2017;48(6):1608–16. https://doi.org/10.1161/STROKEAHA.117.016720.CrossRefPubMedPubMedCentral

163.

Butcher KS, Ng K, Sheridan P, Field TS, Coutts SB, Siddiqui M, et al. Dabigatran treatment of acute noncardioembolic ischemic stroke. Stroke. 2020;51(4):1190–8. https://doi.org/10.1161/STROKEAHA.119.027569.CrossRefPubMed

164.

Kate M, Gioia L, Buck B, Sivakumar L, Jeerakathil T, Shuaib A, et al. Dabigatran therapy in acute ischemic stroke patients without atrial fibrillation. Stroke. 2015;46(9):2685–7. https://doi.org/10.1161/STROKEAHA.115.010383.CrossRefPubMed

165.

Chen B, Friedman B, Whitney MA, Winkle JA, Lei IF, Olson ES, et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci. 2012;32(22):7622–31. https://doi.org/10.1523/JNEUROSCI.0369-12.2012.CrossRefPubMedPubMedCentral

166.

Bushi D, Chapman J, Katzav A, Shavit-Stein E, Molshatzki N, Maggio N, et al. Quantitative detection of thrombin activity in an ischemic stroke model. Journal of molecular neuroscience : MN. 2013;51(3):844–50. https://doi.org/10.1007/s12031-013-0072-y.CrossRefPubMed

167.

Machida T, Dohgu S, Takata F, Matsumoto J, Kimura I, Koga M, et al. Role of thrombin-PAR1-PKCtheta/delta axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. Neuroscience. 2017;350:146–57. https://doi.org/10.1016/j.neuroscience.2017.03.026.CrossRefPubMed

168.

Gavard J, Gutkind JS. Protein kinase C-related kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from Galpha12/13 and Galpha11/q. J Biol Chem. 2008;283(44):29888–96. https://doi.org/10.1074/jbc.M803880200.CrossRefPubMedPubMedCentral

169.

Stein ES, Itsekson-Hayosh Z, Aronovich A, Reisner Y, Bushi D, Pick CG, et al. Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke. Sci Rep. 2015;5:7912. https://doi.org/10.1038/srep07912.CrossRefPubMedPubMedCentral

170.

Fujimoto S, Katsuki H, Ohnishi M, Takagi M, Kume T, Akaike A. Thrombin induces striatal neurotoxicity depending on mitogen-activated protein kinase pathways in vivo. Neuroscience. 2007;144(2):694–701. https://doi.org/10.1016/j.neuroscience.2006.09.049.CrossRefPubMed

171.

Rajput PS, Lyden PD, Chen B, Lamb JA, Pereira B, Lamb A, et al. Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models. Neuroscience. 2014;281:229–40. https://doi.org/10.1016/j.neuroscience.2014.09.038.CrossRefPubMedPubMedCentral

172.

Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, Brat DJ, et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A. 2003;100(22):13019–24. https://doi.org/10.1073/pnas.2235594100.CrossRefPubMedPubMedCentral

173.

Wang J, Jin H, Hua Y, Keep RF, Xi G. Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia. Stroke. 2012;43(9):2476–82. https://doi.org/10.1161/strokeaha.112.661819.CrossRefPubMedPubMedCentral

174.

Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke. 2001;32(11):2635–40. https://doi.org/10.1161/hs1101.097390.CrossRefPubMed

175.

Lyden P, Pereira B, Chen B, Zhao L, Lamb J, Lei IF, et al. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke. 2014;45(3):896–9. https://doi.org/10.1161/STROKEAHA.113.004488.CrossRefPubMedPubMedCentral

176.

Ohyama H, Hosomi N, Takahashi T, Mizushige K, Kohno M. Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. Brain Res. 2001;902(2):264–71. https://doi.org/10.1016/s0006-8993(01)02354-x.CrossRefPubMed

177.

Hawkins BT, Gu YH, Izawa Y, del Zoppo GJ. Dabigatran abrogates brain endothelial cell permeability in response to thrombin. J Cereb Blood Flow Metab. 2015;35(6):985–92. https://doi.org/10.1038/jcbfm.2015.9.CrossRefPubMedPubMedCentral

178.

Choi HJ, Kim NE, Kim J, An S, Yang SH, Ha J, et al. Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization. Thromb Res. 2018;167:165–71. https://doi.org/10.1016/j.thromres.2018.04.019.CrossRef

179.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.CrossRefPubMed

180.

Sinha RK, Wang Y, Zhao Z, Xu X, Burnier L, Gupta N, et al. PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood. 2018;131(11):1163–71. https://doi.org/10.1182/blood-2017-10-810895.CrossRefPubMedPubMedCentral

181.

Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C, protease activated receptor 1, and neuroprotection. Blood. 2018;132(2):159–69. https://doi.org/10.1182/blood-2018-02-769026.CrossRefPubMedPubMedCentral

182.

Gall SL, Donnan G, Dewey HM, Macdonell R, Sturm J, Gilligan A, et al. Sex differences in presentation, severity, and management of stroke in a population-based study. Neurology. 2010;74(12):975–81. https://doi.org/10.1212/WNL.0b013e3181d5a48f.CrossRefPubMed

183.

Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915–26. https://doi.org/10.1016/S1474-4422(08)70193-5.CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy

Neurovascular Units and Neural-Glia Networks in Intracerebral Hemorrhage: from Mechanisms to Translation

Efficacy and Safety of Intravenous rtPA in Ischemic Strokes Due to Small-Vessel Occlusion: Systematic Review and Meta-Analysis

Microglial Responses to Brain Injury and Disease: Functional Diversity and New Opportunities

Recanalization Therapy for Acute Ischemic Stroke with Large Vessel Occlusion: Where We Are and What Comes Next?

Ten Years and Counting: a Celebration of the 10th Anniversary of Translational Stroke Research